CRISPR Therapeutics CRSP Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's accounts payable?
- CRISPR Therapeutics (CRSP) reported accounts payable of $13.65M in Q1 2026.
- How has CRISPR Therapeutics's accounts payable changed year-over-year?
- CRISPR Therapeutics's accounts payable increased by 4.5% year-over-year, from $13.06M to $13.65M.
- What is the long-term trend for CRISPR Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's accounts payable has grown at a 4.1% compound annual growth rate (CAGR), from $9.09M to $11.14M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.